Argen-X (ARGX)

Currency in EUR
607.40
+5.60(+0.93%)
Closed·
ARGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
600.00613.80
52 wk Range
456.60810.00
Key Statistics
Prev. Close
601.8
Open
612.8
Day's Range
600-613.8
52 wk Range
456.6-810
Volume
137.13K
Average Volume (3m)
94.04K
1-Year Change
10.0761%
Book Value / Share
101.85
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
839.27
Upside
+38.17%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Argen-X News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Employees
1863
Market
Belgium

Compare ARGX to Peers and Sector

Metrics to compare
ARGX
Peers
Sector
Relationship
P/E Ratio
33.5x27.5x−0.4x
PEG Ratio
0.630.510.00
Price/Book
5.9x3.9x2.6x
Price / LTM Sales
10.2x3.2x3.1x
Upside (Analyst Target)
43.5%38.5%57.3%
Fair Value Upside
Unlock19.5%8.0%Unlock

Analyst Ratings

13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 839.27
(+38.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Buy725.00+19.36%675.00Upgrade11/03/2026
Barclays
Buy900.00+48.17%880.00Maintain02/03/2026
Barclays
Buy880.00+44.88%850.00Maintain07/01/2026
UBS
Hold910.00+49.82%800.00Maintain09/12/2025
Citi
Buy1,124.00+85.05%1,041.00Maintain18/11/2025

Earnings

Latest Release
26/02/2026
EPS / Forecast
6.80 / 5.07
Revenue / Forecast
1.12B / 1.1B
EPS Revisions
Last 90 days

People Also Watch

68.25
AOO
+0.07%
22.14
WDPP
-0.63%
32.75
RXL
-1.24%
26.10
BVI
-1.51%
29.92
AALB
-0.93%

FAQ

What Is the Argen-X (ARGX) Share Price Today?

The Argen-X stock price today is 607.40 EUR.

What Stock Exchange Does Argen-X (ARGX) Trade On?

Argen-X is listed and trades on the Brussels Stock Exchange.

What Is the Ticker (Stock Symbol) for Argen-X?

The stock symbol (also called a 'ticker') for Argen-X is "ARGX."

What Is the Current Argen-X Market Cap?

As of today, Argen-X market cap is 37.45B EUR.

What Is Argen-X's (ARGX) Earnings Per Share (TTM)?

The Argen-X EPS is currently 19.57 (Trailing Twelve Months).

When Is the Next Argen-X Earnings Date?

Argen-X's next earnings report will be released on 07/05/2026.

Is ARGX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Argen-X moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Argen-X Stock Split?

Argen-X has split 0 times. (See the ARGX stock split history page for full effective split date and price information.)

How Many Employees Does Argen-X Have?

Argen-X has 1863 employees.

What is the current trading status of Argen-X (ARGX)?

As of 27/03/2026, Argen-X (ARGX) is trading at a price of 607.40 EUR, with a previous close of 601.80 EUR. The stock has fluctuated within a day range of 600.00 EUR to 613.80 EUR, while its 52-week range spans from 456.60 EUR to 810.00 EUR.

What Is Argen-X (ARGX) Price Target According to Analysts?

The average 12-month price target for Argen-X is 839.27 EUR, with a high estimate of 991 EUR and a low estimate of 600 EUR. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +38.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.